美国食品和药物管理局授予Rusfertide突破性治疗地位,用于治疗与多细胞血症相关的血液疾病. FDA grants Breakthrough Therapy status to Rusfertide for treating a blood disorder linked to polycythemia vera.

FDA 已授予 Rusfertide 突破性疗法称号，用于治疗真性红细胞增多症 （PV） 患者的红细胞增多症。 The FDA has granted Breakthrough Therapy Designation to Rusfertide for treating erythrocytosis in patients with polycythemia vera (PV). 这一指定得到了第3阶段积极研究结果的支持,目的是加快药物的研制和审查,为目前这种血液紊乱的治疗提供潜在益处。 This designation, supported by positive Phase 3 study results, aims to expedite the drug's development and review, offering potential benefits over current treatments for this blood disorder. 与Takeda制药公司共同开发的Rusfertide公司正按计划在2025年底之前提交新的药物应用申请。 Rusfertide, co-developed with Takeda Pharmaceuticals, is on track for a New Drug Application submission by the end of 2025.